IRVINE, Calif. & AMSTERDAM, Netherlands (October 30, 2023) – Agendia NV, a world leader in precision oncology for breast cancer announced today that the Dutch National Healthcare Institute (ZIN) has approved MammaPrint® for inclusion in the Dutch National health insurance basic package with immediate effect. Based on the MINDACT study data, ZIN affirmed that MammaPrint meets reimbursement criteria, paving the way for its inclusion. The reimbursement is applicable to women over 50 with hormone-positive, HER2-negative breast cancer and 0-3 lymph nodes involved (with clinical high risk). This significant decision, rendered by ZIN, represents a substantial step towards personalized care for women affected by breast cancer in the Netherlands.
MammaPrint analyzes 70 genes most predictive of breast cancer recurrence to provide a binary Low or High Risk of cancer recurrence result. This essential information helps breast cancer patients, and their doctors, to individualize how they manage their patients’ treatment regimen to minimize unnecessary treatment with chemotherapy, retain quality of life, and ensure the best possible outcomes.
“The addition of the MammaPrint test to the basic insurance package in the Netherlands represents a significant step forward for women battling breast cancer. It also stands as a commendation for all our efforts in the Netherlands, the birthplace of MammaPrint over two decades ago”, said CEO Mark Straley. “This inclusion gives women with breast cancer access to Agendia’s cutting-edge diagnostics that serve as the cornerstone for tailored treatment choices. We appreciate the Dutch Healthcare Institute’s acknowledgment of the significance of precision medicine and eagerly anticipate our ongoing contribution to improving outcomes for breast cancer patients in the Netherlands.”
For the past two decades, Agendia’s MammaPrint breast cancer test has played a pivotal role in individualized breast cancer treatment in the Netherlands. With the inclusion of the MammaPrint test in the health insurance basic package, accessibility to personalized care is broadened for women who wish to undergo this test in the Netherlands. This is relevant for about one-third of all hormone-positive HER2-negative early-stage breast cancer in the Netherlands.
“I’m thrilled about ‘Zorginstituut Nederland’s’ decision to include MammaPrint in the Dutch National basic health insurance package, marking a milestone healthcare in my home country”, stated professor Laura van ‘t Veer, Chief Research Officer and co-founder of Agendia alongside Professor René Bernards back in 2003 as a spin-out from the Antoni van Leeuwenhoek. “This recognition of MammaPrint’s precision empowers women and their doctors to make informed treatment choices, avoiding unnecessary procedures and emphasizing personalized care. The reimbursement underscores our commitment to patient-focused, evidence-based medicine, delivering a powerful message about women’s well-being. It’s a pivotal moment where science, compassion, and policy converge to improve the lives of breast cancer patients. My heartfelt thanks to all dedicated Agendia employees for 20 years of tireless work.”
Agendia, spin-out of the Antoni van Leeuwenhoek, is a leading molecular diagnostics company based in Amsterdam and Irvine (CA) in the US, specializing in molecular diagnostics for breast cancer care. We are dedicated to improving the treatment and care of breast cancer patients worldwide through innovative diagnostic solutions. Our MammaPrint and BluePrint test are some of the world’s most advanced gene expression profiling tests that help physicians make personalized treatment decisions. Agendia’s products are available in more than 50 countries and are used by healthcare providers worldwide to improve the care of breast cancer patients.